Innate Pharma Sa Class A · EURONEXT:IPH

Innate Pharma Sa Class A — Technical Presentation (October 2021)

17 slides from Innate Pharma Sa Class A's technical presentation, October 2021

  1. Slide 1: Lacutamab in patients with mycosis fungoides according to KIR3DL2 expression: early results from TELLOMAK

    LACUTAMAB IN PATIENTS (PTS) WITH MYCOSIS FUNGOIDES (MF) ACCORDING TO KIR3DL2 EXPRESSION: EARLY RESULTS FROM THE TELLOMAK PHASE 2 TRIAL Martine Bagot 1, Youn Kim 2, Pier Luigi Zinzani 3, Stephane Dalle 4, Marie Beylot-Barry 5, Pablo L. Ortiz-Romero 6, Andrea Cambalia 7, Olivier Dereure 8, Laurent Mor

  2. Slide 2: Conflict of Interest Disclosure – Martine Bagot

    Conflict of Interest Disclosure – Martine Bagot - Employment or leadership position: N/A - Consultant or advisory role: Innate Pharma, Kyowa Kirin, Takeda, Galderma, Helsinn/Recordati - Stock ownership: N/A - Honoraria: N/A - Research funding: N/A - Other remuneration: N/A Bagot M, 16-ICML 2021

  3. Slide 3: Background

    Background Bagot M, 16-ICML 2021

  4. Slide 4: Lacutamab: first-in-class anti-KIR3DL2 humanized antibody

    LACUTAMAB FIRST-IN-CLASS ANTI-KIR3DL2 HUMANIZED ANTIBODY Lacutamab VL IPH4102 Mycosis Sézary KIR3DL2 Fungoides Syndrome D0 KIR3DL2 ~ 50% of > 90% of D1 expression patients patients VH D2 Marie-Cardine A et al, Cancer Res 2014 Sponsor: Innate Pharma Battistella M et al, Blood 2017 Bagot M, 16-ICML 20

  5. Slide 5: Results of first-in-human phase 1 study

    RESULTS OF FIRST-IN-HUMAN PHASE 1 STUDY GOOD SAFETY PROFILE AND HIGH ACTIVITY OF LACUTAMAB IN SÉZARY SYNDROME • Cutaneous T cell lymphoma = 44 > Sézary syndrome = 35 patients • ≥ 2 prior systemic therapies • No DLT, MTD not reached • RP2D: 750mg IV infusion • Global response: 42.9% (95%CI: 28 – 59)

  6. Slide 6: Patients and Methods

    Patients and Methods Bagot M, 16-ICML 2021

  7. Slide 7: TELLOMAK: T-cell lymphoma anti-KIR3DL2 therapy

    TELLOMAK : T-CELL LYMPHOMA ANTI-KIR3DL2 THERAPY A Multi-cohort International Open-label Phase 2 Trial Lacutamab monotherapy 750mg (1 hour IV infusion) • weekly x 5, every 2 weeks x 10, every 4 weeks until progression or unacceptable toxicity. Cohort # 1 Sézary Syndrome ≥ 2 prior systemic therapies t

  8. Slide 8: Main study endpoints

    MAIN STUDY ENDPOINTS • Primary endpoint > Overall response rate (Global confirmed response) according to the international consensus criteria 1 • Disease evaluation ▪ Skin (mSWAT), Blood (central flow cytometry), Lymph node and viscera (CT or PET/CT) ▪ At week 5 then every 8 weeks x 1 year followed

  9. Slide 9: Key eligibility criteria

    KEY ELIGIBILITY CRITERIA • Mycosis fungoides cohorts > Relapsed and/or refractory stage IB, IIA, IIB, III, IV; > ECOG performance status ≤2; > KIR3DL2 ≥ 1% (Cohort 2) or <1% (Cohort 3) in at least one skin lesion based on central evaluation by immunohistochemistry (IHC); > No evidence of large cell

  10. Slide 10: Preliminary Results from Stage 1 of the MF Cohorts

    Preliminary Results from Stage 1 of the MF Cohorts Bagot M, 16-ICML 2021

  11. Slide 11: Patient characteristics

    PATIENT CHARACTERISTICS • Cohort 2: 17 / 21 recruited in Stage 1 (recruitment ongoing) • Cohort 3: 19 / 18 recruited in Stage 1 (recruitment completed) Cohort 2 Cohort 3 KIR3DL2 ≥ 1% KIR3DL2 < 1% (N=17) (N=19) Age in years, Median (range) 59 (33 – 76) 60 (19 – 81) - Female 6 (35%) 3 (16%) - Male 11

  12. Slide 12: Global response and duration

    GLOBAL RESPONSE AND DURATION MEDIAN FU = 4.8 MONTHS 4 confirmed (1CR, 3PR) & 2 not yet confirmed (uPR) global responses 2 confirmed global responses (2PR) 9 / 17 patients still ongoing therapy 11 / 19 patients still ongoing therapy * reported after DCO date CR: complete response, PR: partial respons

  13. Slide 13: Response by compartment: Cohort 2 – KIR3DL2 ≥ 1%

    RESPONSE BY COMPARTMENT COHORT 2 – KIR3DL2 ≥ 1% Skin (N = 17) uPR Involved at Compartment Responses baseline Skin 17 1CR, 8PR, 2uPR Blood 7 4CR Lymph node 8 1PR Viscera 0 - * reported after DCO date N: number, CR: complete response, PR: partial response, uPR: unconfirmed partial response Bagot M, 16

  14. Slide 14: Response by compartment: Cohort 3 – KIR3DL2 < 1%

    RESPONSE BY COMPARTMENT COHORT 3 – KIR3DL2 < 1% Skin (N = 19) Involved at Compartment Responses baseline Skin 19 2 PR Blood 2 - Lymph node 6 - Viscera 0 - * reported after DCO date N: number, CR: complete response, PR: partial response Bagot M, 16-ICML 2021 Page 14

  15. Slide 15: Treatment related adverse events (at least 5%)

    TREATMENT RELATED ADVERSE EVENTS* (AT LEAST 5%) COHORT 2 + 3 (N = 36) Any grade Grade 3 / 4 Asthenia 4 (11%) 0 Nausea 4 (11%) 0 Arthralgia 2 (6%) 0 Diarrhea 2 (6%) 0 Fatigue 2 (6%) 0 AEs leading to treatment discontinuation 1 (3%) 1 (3%)^ Serious adverse events 1 (3%) 1 (3%) ^ Fatal adverse events 0

  16. Slide 16: TELLOMAK conclusions

    TELLOMAK CONCLUSIONS • In MF patients, KIR3DL2 ≥ 1% appears to be more associated with advanced stage disease, blood and lymph node involvement in comparison to KIR3DL2 <1%. • Lacutamab shows high level of clinical response in MF patients with KIR3DL2 expression ≥ 1%. Expansion to stage 2 is underwa

  17. Slide 17: October 14-16, 2021 Marseille

    Hémicycle de MPM Jardin du Pharo October 14- 58, boulevard Charles Livon 13007 – Marseille FRANCE 16, 2021 www.eortccltf20-21.com

Innate Pharma — Technical Presentation (October 2021) on 6ix